title: Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
abstract: A 57-year-old man with a history of coronary artery disease and placement of an implantable cardioverter-defibrillator presented at our emergency room with an anterior ST-elevation myocardial infarction. Cardiac catheterization revealed an acutely occluded left main coronary artery, which was revascularized successfully with a bare-metal stent. Periprocedurally, the patient received aspirin, clopidogrel, unfractionated heparin, and eptifibatide. The patient was discharged a week later, but he returned to the emergency room the same day with recurrence of severe chest pain. Repeat cardiac catheterization revealed an acutely occluded stent, and the patient underwent repeat bare-metal stent placement and readministration of eptifibatide. On the next day, the patient's platelet count dropped acutely to less than 12,000/mm3. A test for heparin-induced thrombocytopenia antibody was negative. After discontinuation of eptifibatide, the patient's platelet count gradually returned to normal, and he was later discharged from the hospital with no complications. Eptifibatide-induced acute thrombocytopenia is a known but rare adverse effect. We review the handful of case reports in the medical literature, with emphasis on the prevalence, observed clinical course, and recently proposed physiologic mechanisms that probably are responsible for this phenomenon.
authors.affiliation: Division of Cardiology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509, USA. Datsunian@gmail.com
authors.forename: Eric H
authors.initials: EH
authors.lastname: Yang
authors.forename: Edwin
authors.initials: E
authors.lastname: Perez
authors.forename: Katrine A
authors.initials: KA
authors.lastname: Zhiroff
authors.forename: Steven
authors.initials: S
authors.lastname: Burstein
mesh_terms: D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D001241:Aspirin / Q000008:administration & dosage; D006328:Cardiac Catheterization; D000077144:Clopidogrel; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000628:therapy*; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D000077542:Eptifibatide; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D010976:Platelet Count; D015607:Stents; D017131:Thrombectomy; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077144:Clopidogrel; D000077542:Eptifibatide; D013988:Ticlopidine; D001241:Aspirin